235 related articles for article (PubMed ID: 15841634)
121. Imiquimod.
Jobanputra KS; Rajpal AV; Nagpur NG
Indian J Dermatol Venereol Leprol; 2006; 72(6):466-9. PubMed ID: 17179631
[No Abstract] [Full Text] [Related]
122. Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases-a phase II, single centre, randomised, pilot study.
Read T; Webber S; Thomas J; Wagels M; Schaider H; Soyer HP; Smithers BM
BMJ Open; 2017 Oct; 7(10):e016816. PubMed ID: 28988173
[TBL] [Abstract][Full Text] [Related]
123. [Dermoscopic signs as predictors of non-response to imiquimod treatment in superficial basal cell carcinoma].
Aróstegui Aguilar J; Hervella Garcés M; Yanguas Bayona JI; Azcona Rodríguez M; Martínez de Espronceda Ezquerro I; Sarriugarte Aldecoa-Otalora J
An Sist Sanit Navar; 2019 Dec; 42(3):303-307. PubMed ID: 31859267
[TBL] [Abstract][Full Text] [Related]
124. Sequential treatment of daylight photodynamic therapy and imiquimod 5% cream for the treatment of superficial basal cell carcinoma on sun exposed areas.
Paolino G; Didona D; Scarnò M; Tallarico M; Cantoresi F; Calvieri S; Mercuri SR; Piccolo D; Bottoni U; Kyriakou A; Cantisani C
Dermatol Ther; 2019 Mar; 32(2):e12788. PubMed ID: 30499211
[No Abstract] [Full Text] [Related]
125. Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened.
Tang T; Tang JY; Li D; Reich M; Callahan CA; Fu L; Yauch RL; Wang F; Kotkow K; Chang KS; Shpall E; Wu A; Rubin LL; Marsters JC; Epstein EH; Caro I; de Sauvage FJ
Clin Cancer Res; 2011 May; 17(10):3378-87. PubMed ID: 21558397
[TBL] [Abstract][Full Text] [Related]
126. Photodynamic therapy for superficial basal cell carcinomas: Clinical features of partial responses and recurrences.
Condorelli AG; Motolese A; Borgia F; Bartolomeo LD; Bianchi L; Rossi PG; Ottone M; Guarneri F; Motolese A
Photodiagnosis Photodyn Ther; 2022 Mar; 37():102727. PubMed ID: 35041983
[TBL] [Abstract][Full Text] [Related]
127. Topical imiquimod monotherapy for a recurrent lesion of Merkel cell carcinoma.
Miura H; Takada M; Fujiwara M; Fujiwara S
Br J Dermatol; 2021 Feb; 184(2):e30. PubMed ID: 32845515
[No Abstract] [Full Text] [Related]
128. Imiquimod-induced hypertrophic lupus erythematosus-like reaction.
Safadi MG; Hassan S; Patel V; Viglione M; Zahner SL
Dermatol Online J; 2022 Aug; 28(4):. PubMed ID: 36259863
[TBL] [Abstract][Full Text] [Related]
129. Mucosal side effects in patients treated with topical imiquimod-A scoping review of the literature.
Hammerl V; Parlar B; Navarini A; Gantenbein L; Väth H; Mueller SM
Dermatol Ther; 2021 Jan; 34(1):e14355. PubMed ID: 32990395
[TBL] [Abstract][Full Text] [Related]
130. Successful treatment of topical imiquimod-resistant basal cell carcinoma by electronic X-ray brachytherapy.
Sun Y; Su YC; Ke CK; Cheng ST
Dermatol Ther; 2020 Jul; 33(4):e13609. PubMed ID: 32418264
[No Abstract] [Full Text] [Related]
131. Imiquimod as Local Immunotherapy in the Management of Premalignant Cutaneous Conditions and Skin Cancer.
Garcia-Mouronte E; Berna-Rico E; de Nicolas-Ruanes B; Azcarraga-Llobet C; Alonso-Martinez de Salinas L; Bea-Ardebol S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446011
[TBL] [Abstract][Full Text] [Related]
132. Prognostic factors for treatment failure of imiquimod treatment in basal cell carcinoma - an observational study.
Verkouteren BJA; Oostewechel LCF; Nelemans PJ; Sinx KAE; Arits AHMM; Vernemmen AIP; Winnepenninckx VJL; Kelleners-Smeets NWJ; Mosterd K
J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e475-e477. PubMed ID: 35073428
[No Abstract] [Full Text] [Related]
133. Line-Field Confocal Optical Coherence Tomography May Enhance Monitoring of Superficial Basal Cell Carcinoma Treated with Imiquimod 5% Cream: A Pilot Study.
Verzì AE; Micali G; Lacarrubba F
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638396
[TBL] [Abstract][Full Text] [Related]
134. Immunocryosurgery is a safe and feasible treatment for basal cell carcinoma and Bowen disease in renal transplant recipients.
Tsironi T; Gaitanis G; Pappas C; Koutlas V; Dounousi E; Bassukas ID
Dermatol Ther; 2022 May; 35(5):e15405. PubMed ID: 35194902
[TBL] [Abstract][Full Text] [Related]
135. Deep Shave Removal of Suspected Basal Cell Carcinoma: A Prospective Study.
Dando EE; Abban C; Shehu Wingrove A; Pugliano-Mauro M; Ferris L; Ho J; Patton T
Dermatol Surg; 2023 Feb; 49(2):130-134. PubMed ID: 36728062
[TBL] [Abstract][Full Text] [Related]
136. Efficacy and safety of imiquimod 5% cream for basal cell carcinoma: a meta-analysis of randomized controlled trial.
Jia HX; He YL
J Dermatolog Treat; 2020 Dec; 31(8):831-838. PubMed ID: 31294669
[No Abstract] [Full Text] [Related]
137. Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis.
Turza K; Dengel LT; Harris RC; Patterson JW; White K; Grosh WW; Slingluff CL
J Cutan Pathol; 2010 Jan; 37(1):94-8. PubMed ID: 19602071
[TBL] [Abstract][Full Text] [Related]
138. Efficacy and Safety of Laser-Assisted Combination Chemotherapy: An Explorative Imaging-Guided Treatment With 5-Fluorouracil and Cisplatin for Basal Cell Carcinoma.
Wenande E; Hendel K; Mogensen M; Bagger C; Mårtensson NL; Persson DP; Lerche CM; Husted S; Janfelt C; Togsverd-Bo K; Anderson RR; Haedersdal M
Lasers Surg Med; 2021 Jan; 53(1):119-128. PubMed ID: 32960987
[TBL] [Abstract][Full Text] [Related]
139. Facial Basal Cell Carcinoma Treated with Topical 5% Imiquimod Cream with Dermoscopic Evaluation.
Singal A; Daulatabad D; Pandhi D; Arora VK
J Cutan Aesthet Surg; 2016; 9(2):122-5. PubMed ID: 27398014
[TBL] [Abstract][Full Text] [Related]
140. Topical imiquimod treatment of cutaneous vascular disorders in pediatric patients: clinical evaluation on the efficacy and safety.
Mao XH; Wang JY; Yan JL
J Zhejiang Univ Sci B; 2012 Sep; 13(9):745-50. PubMed ID: 22949365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
